NEJM January 28,2026 Nivolumab for Resected Stage III or IV Melanoma at 9 Years

The provided text details the long-term results of the CheckMate 238 clinical trial, which evaluated the effectiveness of two immunotherapy drugs in preventing the return of advanced melanoma after surgery. Over a nine-year follow-up period, researchers discovered that patients treated with nivolumab experienced significantly longer recurrence-free survivalcompared to those who received ipilimumab. While both medications showed high rates of overall survival, nivolumab proved superior in delaying the spread of cancer and reducing the necessity for subsequent systemic treatments. Ultimately, the study concludes that nivolumab provides a sustained clinical advantage, offering a more durable defense against cancer relapse without any new long-term safety concerns.